Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Ensayo clínico de solución nebulizadora de molgramostim inhalado en proteinosis alveolar pulmonar autoinmune (aPAP) (IMPALA-2)

10 de octubre de 2026 actualizado por: Savara Inc.

Ensayo clínico aleatorizado, doble ciego, controlado con placebo de la solución nebulizadora de molgramostim inhalada una vez al día en sujetos adultos con proteinosis alveolar pulmonar autoinmune (aPAP)

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.

Descripción general del estudio

Descripción detallada

This is an interventional, randomized, double-blind, 2-arm, parallel groups, placebo-controlled, multi-center, phase 3 trial in adult subjects who are diagnosed with aPAP.

An aPAP diagnosis should be confirmed by a Granulocyte-macrophage colony stimulating factor (GM-CSF) auto-antibody test result, and history of PAP based on either high resolution computed tomography, lung biopsy, or bronchoalveolar lavage cytology, should be available.

The trial consists of a 6-week screening period, a 48-week randomized, double-blind treatment period, a 96-week open-label treatment period, and a conditional 4-week safety follow-up period. The maximum treatment duration will be 145 weeks and the maximum trial duration will be 156 weeks. During the trial, whole lung lavage will be allowed as rescue treatment in case of worsening of aPAP.

Tipo de estudio

Intervencionista

Inscripción (Actual)

164

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Alemania, 69126
        • Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg
    • Bavaria
      • Muenchen-Gauting, Bavaria, Alemania, 82131
        • Asklepios Fachkliniken Muenchen-Gauting
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Alemania, 45239
        • Ruhrlandklinik Westdeutsches Lungenzentrum
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Royal Prince Alfred Hospital
      • Westmead, New South Wales, Australia, 2145
        • Westmead Hospital
    • Brussels Capital
      • Brussels, Brussels Capital, Bélgica, 1070
        • Hôpital Erasme
    • Vlaams Brabant
      • Leuven, Vlaams Brabant, Bélgica, 3000
        • UZ Leuven - Campus Gasthuisberg - Pneumologie
    • Alberta
      • Calgary, Alberta, Canadá, T2N 4N1
        • University of Calgary
    • Ontario
      • Hamilton, Ontario, Canadá, L8N 4A6
        • St Joseph's Healthcare Hamilton Research
    • Quebec
      • Québec, Quebec, Canadá, G1V 4G5
        • University Institute of Cardiology and Respirology of Quebec
      • Seoul, Corea del Sur, 03080
        • Seoul National University Hospital
      • Seoul, Corea del Sur, 05505
        • Asan Medical Center
      • Seoul, Corea del Sur, 06351
        • Samsung Medical Center
      • Seoul, Corea del Sur, 03722
        • Severance Hospital - Yonsei University Health System - Pulmonary
    • Catalonia
      • Barcelona, Catalonia, España, 08907
        • Hospital Universitario de Bellvitge
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • University Of Arkansas For Medical Services
    • California
      • Los Angeles, California, Estados Unidos, 90095
        • UCLA David Geffen School of Medicine
    • Colorado
      • Denver, Colorado, Estados Unidos, 80206
        • National Jewish Health
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06520
        • Yale University
    • Florida
      • Gainesville, Florida, Estados Unidos, 32610
        • University of Florida Health
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Emory University
    • Illinois
      • Maywood, Illinois, Estados Unidos, 60153
        • Loyola University
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • University of Maryland Medical Center
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University in St. Louis
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke University Medical Center
      • Raleigh, North Carolina, Estados Unidos, 27610
        • Wake Med Health & Hospital
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45229-3039
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • University of Pennsylvania Perelman School of Medicine - Pulmonology
      • Pittsburgh, Pennsylvania, Estados Unidos, 15213
        • University of Pittsburgh
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • UT Southwestern Medical Center
    • Auvergne-Rhône-Alpes
      • Bron, Auvergne-Rhône-Alpes, Francia, 69500
        • Hôpital Louis Pradel
    • Brittany Region
      • Rennes, Brittany Region, Francia, 35033
        • CHU Pontchaillou
      • Athens, Grecia, 12462
        • Attikon University Hospital
      • Dublin, Irlanda, DO4 T6F4
        • St. Vincent's University Hospital
    • Lombardy
      • Pavia, Lombardy, Italia, 27100
        • Fondazione IRCCS Policlinico San Matteo
      • Nagakute, Japón, 480-1195
        • Aichi Medical University Hospital
    • Chiba
      • Chiba, Chiba, Japón, 260-8677
        • Chiba University Hospital - Respiratory Medicine
    • Hokkaidô
      • Sapporo, Hokkaidô, Japón, 060-8648
        • Hokkaido University Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japón, 236-0051
        • Kanagawa Cardiovascular and Respiratory Center
    • Kumamoto
      • Kumamoto, Kumamoto, Japón, 860-8556
        • Kumamoto University Hospital
    • Miyagi
      • Sendai, Miyagi, Japón, 980-8574
        • Tohoku University Hospital - Respiratory Tract Medicine
    • Osaka
      • Sakai, Osaka, Japón, 591-8555
        • National Hospital Organization Kinki-Chuo Chest medical Center
    • Saitama
      • Saitama, Saitama, Japón, 330-8553
        • Saitama Red Cross Hospital
    • Tokyo
      • Mitaka, Tokyo, Japón, 181-8611
        • Kyorin University Hospital
    • Utrecht
      • Nieuwegein, Utrecht, Países Bajos, 3435CM
        • St Antonius Hospital
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polonia, 01-138
        • Instytut Gruzlicy i Chorob Pluc
    • Lisbon District
      • Lisbon, Lisbon District, Portugal, 1769-001
        • Hospital Pulido Valente
    • Porto District
      • Porto, Porto District, Portugal, 4200-319
        • Hospital São João
    • London
      • London, London, Reino Unido, SW3 6NP
        • Royal Brompton and Harefield NHS Foundation Trust
    • Bucharest
      • Bucharest, Bucharest, Rumania, 050159
        • Institutul de Pneumoftiziologie "Marius Nasta"
    • Ankara
      • Ankara, Ankara, Turquía (Türkiye), 6010
        • Health Sciences University Gulhane Training and Research Hospital
    • Istanbul
      • Istanbul, Istanbul, Turquía (Türkiye), 34020
        • Yedikule Chest Disease and Surgery Training and Research Hospital
    • İzmir
      • Bornova, İzmir, Turquía (Türkiye), 35100
        • Ege University Hospital - Department of Pulmonology

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Subject must be ≥18 years of age, at the time of signing the informed consent (≥20 in Japan).

  2. A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.

  3. History of PAP, based on examination of a lung biopsy, bronchoalveolar lavage (BAL) cytology, or a high-resolution computed tomogram (HRCT) of the chest.

  4. A diffusing capacity for carbon monoxide of 70% predicted or lower adjusted for hemoglobin (%DLCOadj) at the screening and baseline visits.

  5. Change in %DLCO adj of <15% points during the screening period.

  6. Demonstrated functional impairment in the treadmill exercise test (defined as a peak metabolic equivalent (MET) ≤8).

  7. Willing and able to come off supplemental oxygen use prior to and during the treadmill exercise test, the DLCO assessment, and the arterial blood gas sampling.

  8. Resting oxygen saturation (SpO2) >85% during 15 minutes without use of supplemental oxygen at the screening visits.

  9. Male or female

  10. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Male subjects: Males agreeing to use condoms during and until 30 days after last dose of trial treatment, or males having a female partner who is using adequate contraception as described below.
    2. Female subjects: Females who have been post-menopausal for >1 year, or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence*), during and until 30 days after last dose of trial treatment. Females of childbearing potential must have a negative serum pregnancy test at the screening visits, and a negative urine pregnancy test at Baseline visit (Visit 3) and must not be lactating.
  11. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

  12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the Investigator.

Exclusion Criteria:

  1. Diagnosis of hereditary or secondary PAP, or a metabolic disorder of surfactant production.
  2. Whole lung lavage (WLL) performed within 3 months prior to baseline.
  3. Requirement for WLL at screening or baseline.
  4. GM-CSF treatment within 6 months prior to baseline.
  5. Treatment with rituximab within 6 months prior to baseline.
  6. Treatment with plasmapheresis within 6 weeks prior to baseline.
  7. Treatment with any investigational medicinal product within 5 half-lives or 3 months (whichever is longer) prior to baseline.
  8. Previously randomized in this trial.
  9. History of allergic reactions to GM-CSF or any of the excipients in the nebulizer solution.
  10. Inflammatory or autoimmune disease of a severity that necessitates significant (e.g. more than 10 mg/day systemic prednisolone) immunosuppression.
  11. Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product.
  12. History of, or present, myeloproliferative disease or leukemia.
  13. Apparent pre-existing concurrent pulmonary fibrosis.
  14. Acute or unstable cardiac or pulmonary disease that may be aggravated by exercise.
  15. Known active infection (viral, bacterial, fungal, or mycobacterial) that may affect the efficacy evaluation in the trial.
  16. Physical disability or other condition that precludes safe and adequate exercise testing.
  17. Any other serious medical condition which in the opinion of the Investigator would make the subject unsuitable for the trial.
  18. Pregnant, planning to become pregnant during the trial, or breastfeeding woman. For France only: including as further defined by French Health Code L-1121-5.
  19. For France only: Any subject considered to be "vulnerable" on account of, e.g., mental or physical disability, socio-economic situation, or subjects deprived of their liberty. For France only: including as further defined by French Health Code L1121-8-1.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Molgramostim

Double-blind treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 48 weeks

Molgramostim 300 µg nebulizer solution

Otros nombres:
  • Factor estimulante de colonias de granulocitos y macrófagos humano recombinante (rhGM-CSF)
Comparador de placebos: Placebo

Double-blind treatment with placebo (PBO) nebulizer solution once daily for 48 weeks

Matching placebo nebulizer solution

Otros nombres:
  • Nebulizador placebo
Experimental: Molgramostim Open-label Extension

Open-label treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 96 weeks

Molgramostim 300 µg nebulizer solution

Otros nombres:
  • Factor estimulante de colonias de granulocitos y macrófagos humano recombinante (rhGM-CSF)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24
Periodo de tiempo: From Baseline to Week 24

As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj).

From Baseline to Week 24

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Percent (%) Predicted DLCO Adjusted for Hemoglobin Concentration (%DLCOadj) to Week 48
Periodo de tiempo: From Baseline to Week 48

As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj). Higher values indicate better respiratory gas exchange.

From Baseline to Week 48
Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score to Week 24
Periodo de tiempo: From Baseline to Week 24

The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health.

From Baseline to Week 24
Change From Baseline in SGRQ Activity Component Score to Week 24
Periodo de tiempo: From Baseline to Week 24

The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity

From Baseline to Week 24
Change From Baseline in Exercise Capacity (EC), Expressed as Peak Metabolic Equivalents (METs) to Week 24
Periodo de tiempo: From Baseline to Week 24

As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity.

From Baseline to Week 24
Change From Baseline in SGRQ Total Score to Week 48
Periodo de tiempo: From Baseline to Week 48

The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health.

From Baseline to Week 48
Change From Baseline in SGRQ Activity From Baseline to Week 48
Periodo de tiempo: From Baseline to Week 48

The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity

From Baseline to Week 48
Change From Baseline in EC, Expressed as Peak METs to Week 48
Periodo de tiempo: From Baseline to Week 48

As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity.

From Baseline to Week 48
Change From Baseline in Alveolar-arterial Oxygen Difference (A-aDO2) to Week 24 (All Subjects)
Periodo de tiempo: From Baseline to Week 24

A-aDO2 was used as an additional measure of gas exchange.

From Baseline to Week 24
Number of Subjects With Serious and Non-serious Adverse Events
Periodo de tiempo: From Baseline until End of Double-blind treatment (Week 48)

Assessment of the safety of molgramostim compared to placebo

From Baseline until End of Double-blind treatment (Week 48)
Number of Subjects With Positive Treatment-boosted Anti Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Antibody Titers During 24 Weeks' Treatment and During 48 Weeks' Treatment
Periodo de tiempo: From Baseline until End of Double-blind treatment Week-48

Assess the effect of molgramostim or placebo on antiGM-CSF antibody titers that increased by a dilution factor of 2.(4X increase in titer compared to Baseline).

From Baseline until End of Double-blind treatment Week-48
Changes in Forced Vital Capacity (FVC) %Predicted Normal
Periodo de tiempo: From Baseline to Weeks 24 and 48

Forced vital capacity is the volume of air that can be expired after a deep breath. Higher volumes indicate better respiratory function. FVC is scored as % of predicted normal expired vital capacity.

From Baseline to Weeks 24 and 48
Changes in Forced Expiratory Volume in One Second (FEV1) % Predicted Normal.
Periodo de tiempo: From Baseline to Weeks 24 and 48

FEV1 is the volume of air expired in 1 second in liters (L). Higher values indicate better respiratory function.

From Baseline to Weeks 24 and 48
Change in QT Interval Corrected by Fridericia (QTcF)
Periodo de tiempo: From Baseline to Weeks 4 and 24

Assessment of the safety of MOL compared to placebo

From Baseline to Weeks 4 and 24

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Bruce Trapnell, MD, Children's Hospital Medical Center, Cincinnati

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de mayo de 2021

Finalización primaria (Actual)

30 de noviembre de 2023

Finalización del estudio (Estimado)

30 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

3 de septiembre de 2020

Primero enviado que cumplió con los criterios de control de calidad

3 de septiembre de 2020

Publicado por primera vez (Actual)

10 de septiembre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir